Ctni antibodies and uses thereof

Abstract

The present application provides a cTnI antibody, which comprises a heavy chain variable region and / or a light chain variable region; the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 1 or a variant thereof, the variant of SEQ ID NO: 1 comprises mutations in at least one of positions 30, 31, 57, 65, 101, 103 and 111, compared with the amino acid sequence shown in SEQ ID NO: 1; and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof, the variant of SEQ ID NO: 2 comprises mutations in at least one of positions 93 and 95, compared with the amino acid sequence shown in SEQ ID NO: 2. The antibody of the present application can effectively bind to cTnI and can be used for qualitative or quantitative detection of cTnI.

Description

[0001] Cross-reference to related applications

[0002] This application claims priority to Chinese Patent Application No. 202310344015.9, filed on March 31, 2023, entitled "cTnI antibody and its use", the entire contents of which are incorporated herein by reference. Technical Field

[0003] This invention belongs to the field of antibody technology. Specifically, this invention relates to a cTnI antibody and its uses. More specifically, this invention relates to a cTnI antibody, nucleic acid molecule, vector, cell or host, antibody preparation method, conjugate, reagent or kit and its uses, method for screening cTnI antibodies, and mutant library. Background Technology

[0004] cTn is composed of three different gene subunits: cardiac troponin T (cTnT), cardiac troponin I (cTnI), and troponin C (TnC). cTnT and cTnI are used for laboratory diagnosis of ACS. cTnI exists in cardiomyocytes and is a marker of cardiomyocyte function. Abnormal changes in cTnI can affect cardiac systolic and diastolic function and can be used to diagnose myocardial necrosis and assess myocardial injury. It has become one of the most sensitive and specific markers of cardiomyocyte damage and is a recognized key biochemical marker for rapid diagnosis of AMI and acute coronary syndromes (ACS), as well as for assisting in ACS risk stratification and reflecting its prognosis.

[0005] Under normal conditions, cTnI cannot penetrate cell membranes to enter the bloodstream, so the cTnI level in the blood of healthy individuals is extremely low. However, in patients with acute myocardial infarction (AMI), cTnI enters the intercellular matrix and blood. cTnI levels rise 3–5 hours after the onset of AMI, peak at 15–24 hours, and remain elevated for a prolonged period, returning to normal after 5–10 days. Currently, cTnI is considered the new "gold standard" for diagnosing myocardial infarction and cardiomyocyte damage. Therefore, there is a strong demand in this field for antibodies that effectively bind to and detect cTnI. Summary of the Invention

[0006] The present invention aims to provide an anti-cTnI antibody, a reagent or kit for detecting cTnI.

[0007] In a first aspect, the present invention provides an anti-cTnI antibody comprising: a heavy chain variable region and / or a light chain variable region; the heavy chain variable region comprising an amino acid sequence as shown in SEQ ID NO:1 or a variant thereof, wherein, compared to the amino acid sequence shown in SEQ ID NO:1, the variant of SEQ ID NO:1 comprises a mutation at at least one of the following positions: position 30, position 31, position 57, position 65, position 101, position 103, and position 111; the light chain variable region comprising an amino acid sequence as shown in SEQ ID NO:2 or a variant thereof, wherein, compared to the amino acid sequence shown in SEQ ID NO:2, the variant of SEQ ID NO:2 comprises a mutation at at least one of the following positions: position 93 and position 95; the heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:1 and the light chain variable region comprising the amino acid sequence shown in SEQ ID NO:2 are not present simultaneously.

[0008] In a second aspect, the present invention provides an anti-cTnI antibody comprising HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 are amino acid sequences consistent with HCDR1, HCDR2, HCDR3 of the heavy chain variable region defined by the antibody described in the first aspect; and wherein LCDR1, LCDR2, LCDR3 are amino acid sequences consistent with LCDR1, LCDR2, LCDR3 of the light chain variable region defined by the antibody described in the first aspect.

[0009] In a third aspect of the invention, the invention provides a nucleic acid molecule, a vector, a cell or host, or a method for preparing the aforementioned antibody, wherein the nucleic acid molecule encodes the antibody described in the first or second aspect; the vector comprises the aforementioned nucleic acid molecule; the cell or host comprises the aforementioned nucleic acid molecule or vector or expresses the aforementioned antibody; and the method comprises culturing the aforementioned cell or host.

[0010] In a fourth aspect of the invention, the invention provides a conjugate comprising: the antibody described in the first or second aspect and a conjugate portion thereto.

[0011] In a fifth aspect of the invention, the invention provides a reagent or kit comprising: the antibody described in the first or second aspect or the conjugate described in the fourth aspect.

[0012] In a sixth aspect of the invention, the invention provides for the use of an antibody described in the first or second aspect, a conjugate described in the fourth aspect, or a reagent or kit described in the fifth aspect in the detection of cTnI, the preparation of products for the detection of cTnI, or the preparation of products for the diagnosis of cTnI-related diseases.

[0013] In a seventh aspect of the invention, a method for screening cTnI antibodies is provided, the method comprising: a) designing primers for replacing amino acids at mutation sites defined in the antibody described in the first or second aspect, or at sites 1, 2, 3, 4, 5, 6, 7, or 8 of X2, X3, X4, X5, X6, X7, X8, and X9 defined in the antibody described in the second aspect; b) constructing a mutant library using the primers described in a) as a template, with the nucleic acid molecule, vector, or cell described in the third aspect; and c) screening cTnI antibodies from the mutant library.

[0014] In an eighth aspect of the invention, the invention provides a mutant library comprising the antibody described in the first or second aspect.

[0015] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. Detailed Implementation

[0016] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0017] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this invention, unless otherwise stated, "a plurality of" means two or more.

[0018] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0019] To facilitate understanding of this invention, certain technical and scientific terms are specifically defined below. Unless explicitly defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention pertains. Abbreviations for amino acid residues are the standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids.

[0020] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this invention, but do not exclude other aspects.

[0021] In this document, the terms “optional,” “optional,” “alternatively,” “optional,” or “optional” generally refer to an event or condition that may or may not occur as described below, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.

[0022] In this paper, the terms “identity,” “homology,” or “similarity” are used to describe the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences relative to a reference sequence, determined by conventional methods, for example, see Ausubel et al., eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN procedure (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research Institute)). Foundation, Washington, DC). There are many algorithms for aligning sequences and determining sequence identity, including: Needleman et al. (1970) J. Mol. Biol. 48: 443, a homology alignment algorithm; Smith et al. (1981) Adv. Appl. Math. 2: 482, a local homology algorithm; Pearson et al. (1988) Proc. Natl. Acad. Sci. 85: 2444, a similarity search method; and the Smith-Waterman algorithm (Meth. Mol. Biol). .70:173-187 (1997); and the BLASTP, BLASTN, and BLASTX algorithms (see Altschul et al. (1990) J.Mol.Biol. 215:403-410). Computer programs utilizing these algorithms are also available, including but not limited to: ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altschul et al., Meth.Enzym., 266:460-480 (1996)); or GAP, BESTFIT, BLAST Altschul et al., above, FASTA, and TFASTA, available in Genetics Computing Group (GCG) package, version 8, Madison, Wisconsin, USA; and CLUSTAL in the PC / Gene program provided by Intelligenetics, Mountain View, California.

[0023] Without substantially affecting antibody activity (retaining at least 90% of the activity), those skilled in the art can substitute, add, and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more) amino acids to obtain variants of the antibody sequence. These are all considered to be included within the scope of protection of this invention. For example, amino acids with similar properties can be substituted in the variable region. The variant sequences of this invention can have at least 90%, 95%, 96%, 97%, 98%, or 99% identity (or homology) with the reference sequence. Sequence identity described in this invention can be measured using sequence analysis software, such as the computer program BLAST using default parameters, especially BLASTP or TBLASTN. The amino acid sequences described in this invention are shown from the N-terminus to the C-terminus.

[0024] It should be noted that the position or number of the mutation sites defined in the specification and claims of this invention also needs to be adjusted according to the number and position of the added and / or deleted amino acids. For example, a variant of SEQ ID NO:1 is obtained by adding an amino acid before the 30th amino acid (e.g., the 10th or 27th position), and those skilled in the art will understand that T30N should be adjusted to T31N; or, a variant of SEQ ID NO:1 is obtained by deleting two amino acids before the 30th amino acid (e.g., the 10th or 27th position), and those skilled in the art will understand that T30N should be adjusted to S28V.

[0025] In this paper, the term "at least 80% homology" refers to at least 80% homology with each reference sequence, which can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9%. The term "at least 90% homology" refers to at least 90% homology with each reference sequence, which can be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9%.

[0026] In this paper, the term “variant” or “mutant” can refer to any naturally occurring or engineered molecule that contains one or more nucleotide or amino acid mutations.

[0027] In this document, the term "vector" generally refers to a nucleic acid molecule capable of self-replication within a suitable host, transferring the inserted nucleic acid molecule into and / or between cells or hosts. The vector may include vectors primarily for inserting DNA or RNA into cells, vectors primarily for replicating DNA or RNA, and expression vectors primarily for transcription and / or translation of DNA or RNA. The vector also includes vectors having multiple of the aforementioned functions. The vector may be a polynucleotide capable of being transcribed and translated into a polypeptide when introduced into a suitable cell or host. Typically, by culturing a suitable cell or host containing the vector, the vector can produce the desired expression product.

[0028] In this document, the term "cell" generally refers to a cell whose genetic material has been modified or recombined using genetic engineering or cell fusion techniques to obtain a unique trait with stable inheritance. The term "host cell" refers to a prokaryotic or eukaryotic cell into which a recombinant vector can be introduced. The terms "transformed" or "transfected" as used herein refer to the introduction of nucleic acids (e.g., vectors) into cells using various techniques known in the art. Suitable host cells can be transformed or transfected with the DNA sequences of this invention and can be used for the expression and / or secretion of target proteins. Examples of suitable host cells that can be used in this invention include immortalized hybridoma cells, NS / O myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, Cap cells (cells derived from human amniotic fluid), and CoS cells.

[0029] This invention proposes a method for preparing antibodies, nucleic acid molecules, vectors, cells or hosts, conjugates, reagents or kits and their uses, a method for detecting cTnI, a method for screening cTnI antibodies, and a mutant library, which will be described in detail below.

[0030] Antibody

[0031] In a first aspect, the present invention provides an anti-cTnI antibody. According to an embodiment of the invention, the antibody comprises: a heavy chain variable region and / or a light chain variable region; the heavy chain variable region comprises / is an amino acid sequence as shown in SEQ ID NO:1 or a variant thereof, wherein, compared to the amino acid sequence shown in SEQ ID NO:1, the variant of SEQ ID NO:1 includes mutations at at least one of positions 30, 31, 57, 65, 101, 103, and 111; the light chain variable region comprises / is an amino acid sequence as shown in SEQ ID NO:2 or a variant thereof, wherein, compared to the amino acid sequence shown in SEQ ID NO:2, the variant of SEQ ID NO:2 includes mutations at at least one of positions 93 and 95; the heavy chain variable region being an amino acid sequence as shown in SEQ ID NO:1 and the light chain variable region being an amino acid sequence as shown in SEQ ID NO:2 do not coexist.

[0032] In this document, the term "antibody" is used in the broadest sense, encompassing full-length monoclonal antibodies, multispecific antibodies, and chimeric antibodies or functional fragments, with no specific structural limitations, as long as they exhibit the desired antigen-binding activity. In this document, the terms "full-length antibody," "full-length monoclonal antibody," or "full-length monoclonal antibody" refer to an antibody molecule composed of at least two identical light chains and at least two identical heavy chains linked by interchain disulfide bonds, such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD), or immunoglobulin E (IgE). It typically comprises a lighter light chain and a heavier heavy chain, with the heavy chain (H chain) and light chain (L chain) linked by disulfide bonds. The amino acid sequence at the amino terminus (N-terminus) of the peptide chain varies considerably and is called the variable region (V region); the carboxyl terminus (C-terminus) is relatively stable and changes very little, and is called the constant region (C region). The V regions of the L chain and H chain are referred to as VL and VH, respectively.

[0033] In this document, the terms "polyclonal antibody" and "multispecific antibody" are synonymous, both referring to antibodies that can recognize multiple antigenic epitopes. For example, antibodies that recognize two antigenic epitopes (bispecific antibodies, or simply biantibodies), three antigenic epitopes, or four antigenic epitopes are used in a broad sense, and their specific structures are not limited, as long as they can recognize multiple antigenic epitopes. In this invention, at least one of the multiple antigenic epitopes is derived from cTnI.

[0034] In this document, the term "functional fragment" refers to a fragment containing part or all of an antibody that lacks at least some of the amino acids present in the full-length chain but still possesses the performance activity of specifically binding to an antigen. For example, the fragment may contain part or all of an antibody CDR. Such fragments are biologically active because they bind to the antigen and can compete with other antigen-binding molecules (including intact antibodies) for binding to a given epitope. Such fragments include Fv fragments, disulfide-stabilized Fv fragments (dsFv), F(ab')2 fragments, Fab' fragments, Fab fragments, F(ab)2 fragments, scFv fragments, scFv-Fc fusion proteins, scFv-Fv fusion proteins, Fv-Fc fusion proteins, multispecific antibodies formed from functional fragments, single-domain antibodies, VHH nanobodies, domain antibodies, bivalent domain antibodies, or at least one of the smallest recognition units. Such fragments can be generated by recombinant nucleic acid technology or by enzymatic or chemical cleavage of antigen-binding molecules (including intact antibodies).

[0035] According to embodiments of the present invention, the antibody may further include at least one of the following additional technical features:

[0036] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO:1, the variant of SEQ ID NO:1 includes mutations at the following sites: T30N, I31L, G57R, K65G, Y101M / I / T, N103P and Y111I / H / M.

[0037] In an optional embodiment of the invention, the mutation at the 30th position is T30N.

[0038] In an optional embodiment of the invention, the mutation at position 31 is I31L.

[0039] In an optional embodiment of the invention, the mutation at position 57 is G57R.

[0040] In an optional embodiment of the invention, the mutation at position 65 is K65G.

[0041] In an optional embodiment of the present invention, the mutation at the 101st position is Y101M.

[0042] In an optional embodiment of the present invention, the mutation at the 101st position is Y101I.

[0043] In an optional embodiment of the present invention, the mutation at the 101st position is Y101T.

[0044] In an optional embodiment of the invention, the mutation at the 103rd position is N103P.

[0045] In an optional embodiment of the invention, the mutation at the 111th position is Y111I.

[0046] In an optional embodiment of the present invention, the mutation at the 111th position is Y111H.

[0047] In an optional embodiment of the invention, the mutation at the 111th position is Y111M.

[0048] It should be noted that the above-mentioned positions are numbered sequentially from the N-terminus to the C-terminus of the amino acid sequence shown in SEQ ID NO:1. For example, position 30 refers to the 30th position from the N-terminus of the amino acid sequence shown in SEQ ID NO:1; "T30N" means that the threonine at position 30 of the amino acid sequence shown in SEQ ID NO:1 is replaced by asparagine; and "Y101M / I / T" means that the tyrosine at position 101 of the amino acid sequence shown in SEQ ID NO:1 can be replaced by methionine, isoleucine, or threonine.

[0049] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO:1, the variant of SEQ ID NO:1 includes mutations at the following sites:

[0050]

[0051]

[0052] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO:2, the variant of SEQ ID NO:2 includes mutations at least one of V93L and S95M.

[0053] It should be noted that the above-mentioned site numbering was obtained by sequentially numbering the amino acid sequence shown in SEQ ID NO:2 from the N-terminus to the C-terminus. For example, position 93 refers to the 93rd position of the amino acid sequence shown in SEQ ID NO:2 starting from the N-terminus; "V93L" means that valine at position 93 of the amino acid sequence shown in SEQ ID NO:2 is replaced by leucine.

[0054] In an optional embodiment of the invention, the mutation at position 93 is V93L.

[0055] In an optional embodiment of the invention, the mutation at the 95th position is S95M.

[0056] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO:2, the variant of SEQ ID NO:2 includes mutations at the following sites:

[0057] mutation site VL variant 1 V93L VL variant 2 S95M VL variant 3 V93L, S95M .

[0058] According to an embodiment of the present invention, the heavy chain variable region and the light chain variable region are selected from any combination of the following:

[0059]

[0060]

[0061] The mutated antibody described in the first aspect of the present invention has improved activity, affinity, stability or specificity compared to the antibody without the mutation described in the first aspect.

[0062] In an optional embodiment of the invention, the affinity KD of the mutated antibody is <10. -9 M.

[0063] In an optional embodiment of the invention, the affinity KD of the mutated antibody is <10. -10 M.

[0064] In an optional embodiment of the invention, the affinity KD of the mutated antibody is <10. -11 M.

[0065] In a second aspect, the present invention provides an antibody. According to an embodiment of the present invention, the antibody comprises HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 are amino acid sequences consistent with HCDR1, HCDR2, HCDR3 of the heavy chain variable region defined by the antibody described in the first aspect; and LCDR1, LCDR2, LCDR3 are amino acid sequences consistent with LCDR1, LCDR2, LCDR3 of the light chain variable region defined by the antibody described in the first aspect.

[0066] It should be noted that HCDR1, HCDR2, and HCDR3 include or are amino acid sequences consistent with HCDR1, HCDR2, and HCDR3 of the same heavy chain variable region defined in the antibody described in the first aspect, and LCDR1, LCDR2, and LCDR3 include or are amino acid sequences consistent with LCDR1, LCDR2, and LCDR3 of the same light chain variable region defined in the antibody described in the first aspect.

[0067] For example, when the heavy chain variable region defined in the antibody described in the first aspect has only a mutation at the I31L site compared to SEQ ID NO:1, and HCDR1, HCDR2, and HCDR3 of this heavy chain variable region are defined in Kabat as HCDR1:LYVLH; HCDR2:YINPYIDGTKYNEKFKG; HCDR3:SGYGNYGLAWLAY, then the HCDR1, HCDR2, and HCDR3 contained in the antibody described in the second aspect are also HCDR1:LYVLH; HCDR2:YINPYIDGTKYNEKFKG; HCDR3:SGYGNYGLAWLAY.

[0068] For example, when the light chain variable region defined in the antibody described in the first aspect has no mutation compared to SEQ ID NO:2, and the LCDR1, LCDR2, and LCDR3 of the light chain variable region are defined in Kabat as LCDR1:RSSTGAVTTSNYAN; LCDR2:GSNNRAP; and LCDR3:ALVYSNNWV, then the LCDR1, LCDR2, and LCDR3 contained in the antibody described in the second aspect are also LCDR1:RSSTGAVTTSNYAN; LCDR2:GSNNRAP; and LCDR3:ALVYSNNWV, respectively.

[0069] As used herein, the terms “complementarity-determining region,” “CDR,” or “CDRs” refer to highly variable regions of the heavy and light chains of immunoglobulins, specifically regions containing one or more or all of the major amino acid residues that contribute to the binding affinity of antibodies to the antigens or epitopes they recognize.

[0070] In this paper, heavy chain complementarity-determining regions (heavy chain variable regions CDRs) are referred to as "HCDRs" or "HCDRs", which include HCDR1 (also known as CDR-H1), HCDR2 (also known as CDR-H2), and HCDR3 (also known as CDR-H3); light chain complementarity-determining regions (light chain variable regions CDRs) are referred to as "LCDRs" or "LCDRs", which include LCDR1 (also known as CDR-L1), LCDR2 (also known as CDR-L2), and LCDR3 (also known as CDR-L3). Commonly used CDR definition schemes in this field include: Kabat definition, Chothia definition, IMGT definition, Contact definition, and AbM definition. As described herein, "Kabat definition" refers to the definition system described by Kabat et al., USD ept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). For the “Chothia definition,” see Chothia et al., J Mol Biol 196:901-917 (1987). Exemplary definitions of CDRs are listed in Table 1 below. Definitions vary slightly in different literature. Given the amino acid sequence of the variable region of an antibody, those skilled in the art can routinely determine which residues contain a specific CDR. It should be noted that the CDRs in this invention include, but are not limited to, CDRs defined by other methods listed in Table 1. CDRs determined based on the heavy chain and light chain variable regions disclosed in this application using other rules disclosed in the art are also within the scope of this disclosure.

[0071] Table 1: CDR Definition 1

[0072] CDR Kabat <![CDATA[AbM 2 ]]> IMGT Chothia HCDR1 <![CDATA[H31~H35 3 ]]> <![CDATA[H26~H35 3 ]]> <![CDATA[H26~H33 5 ]]> <![CDATA[H26~H32..34 4 ]]> HCDR2 H50~H65 H50~H58 H51~H57 H52~H56 HCDR3 H95~H102 H95~H102 H93~H102 H95~H102 LCDR1 L24~L34 L24~L34 L27~L32 L24~L34 LCDR2 L50~L56 L50~L56 L50~L51 L50~L56 LCDR3 L89~L97 L89~L97 L89~L97 L89~L97

[0073] 1 The CDRs defined in Table 1 are numbered according to the Kabat numbering system (see below). The amino acid number on the heavy chain is represented by "H + number", and the amino acid number on the light chain is represented by "L + number".

[0074] 2 As used in Table 1, “AbM” with a lowercase “b” refers to the CDR defined by the “AbM” antibody modeling software of Oxford Molecular.

[0075] 3 If neither H35A nor H35B exists, then CDR-H1 ends at bit 35; if only H35A exists, then CDR-H1 ends at bit 35A; if both H35A and H35B exist, then CDR-H1 ends at bit 35B.

[0076] 4 If neither H35A nor H35B exists, then CDR-H1 ends at bit 32; if only H35A exists, then CDR-H1 ends at bit 33; if both H35A and H35B exist, then CDR-H1 ends at bit 34.

[0077] 5 If neither H35A nor H35B exists, then CDR-H1 ends at bit 33; if only H35A exists, then CDR-H1 ends at bit 34; if both H35A and H35B exist, then CDR-H1 ends at bit 35.

[0078] Kabat et al. also defined a numbering system applicable to the variable region sequences of any antibody. Those skilled in the art can readily map this Kabat numbering system to any variable region sequence without relying on any experimental data outside the sequence itself. As stated herein, "Kabat numbering" refers to numbering using the numbering system described in Kabat et al., USDept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). The HCDRs and LCDRs of the antibodies in this application are numbered using the aforementioned numbering system, and the specific numbering results are shown in Table 1. It should be noted that the sequence listings and peptide sequences in Table 2 of this invention are not numbered according to the Kabat numbering system. However, those skilled in the art can readily convert the sequence listing sequence numbers to Kabat numbers.

[0079] According to embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by any one or a combination of systems such as Kabat, Chothia, IMGT, AbM or Contact.

[0080] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Kabat system.

[0081] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Chothia system.

[0082] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the IMGT system.

[0083] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the AbM system.

[0084] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Contact system.

[0085] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by a combination of Kabat, Chothia, IMGT, AbM, or Contact systems.

[0086] According to embodiments of the present invention, the Kabat numbering positions corresponding to the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, or LCDR3 defined by the Kabat, Chothia, AbM, or IMGT systems are as follows:

[0087]

[0088]

[0089] According to an embodiment of the present invention, the HCDRs and LCDRs are defined by the Kabat system.

[0090] In some optional embodiments of the present invention, the HCDRs and LCDRs are defined by the Kabat system, and the HCDRs and LCDRs are amino acid sequences as shown below:

[0091] HCDR 1:X2YVLH, where X2 is I or L;

[0092] HCDR 2:YINPYIDX3TKYNEKFX4G, where X3 is G or R, and X4 is K or G;

[0093] HCDR 3:SGX5GX6YGLAWLAX7, where X5 is Y, M, I or T, X6 is N or P, and X7 is Y, I, H or M;

[0094] LCDR 1:RSSTGAVTTSNYAN;

[0095] LCDR 2:GSNNRAP;

[0096] LCDR 3:ALX8YX9NNWV, where X8 is V or L, and X9 is S or M.

[0097] As can be seen from the definition principles in the aforementioned table, different systems will yield different CDRs, even for the same heavy chain variable region or the same light chain variable region. In this application, "HCDR 1:X2YVLH" refers to HCDR 1 whose amino acid sequence includes or is X2YVLH. This can also be adjusted according to different systems to obtain HCDR 1 with a sequence longer than X2YVLH. For example, HCDR 1 is defined by the AbM system as GYTFX1X2YVLH, where X1 is T or N.

[0098] In some optional embodiments of the present invention, X2 being I, X3 being G, X4 being K, X5 being Y, X6 being N, X7 being Y, X8 being V, and X9 being S do not coexist. In some optional embodiments of the present invention, X2 is I.

[0099] In some optional embodiments of the present invention, X2 is L;

[0100] In some alternative embodiments of the present invention, X3 is G.

[0101] In some alternative embodiments of the present invention, X3 is R.

[0102] In some alternative embodiments of the present invention, X4 is K.

[0103] In some optional embodiments of the present invention, X4 is G;

[0104] In some alternative embodiments of the present invention, X5 is Y.

[0105] In some alternative embodiments of the present invention, X5 is M.

[0106] In some alternative embodiments of the present invention, X5 is I.

[0107] In some alternative embodiments of the present invention, X5 is T.

[0108] In some alternative embodiments of the present invention, X6 is N.

[0109] In some alternative embodiments of the present invention, X6 is P.

[0110] In some alternative embodiments of the present invention, X7 is Y.

[0111] In some alternative embodiments of the present invention, X7 is I.

[0112] In some alternative embodiments of the present invention, X7 is H.

[0113] In some alternative embodiments of the present invention, X7 is M.

[0114] In some alternative embodiments of the present invention, X8 is V.

[0115] In some alternative embodiments of the present invention, X8 is L.

[0116] In some alternative embodiments of the present invention, X9 is S.

[0117] In some alternative embodiments of the present invention, X9 is M.

[0118] According to an embodiment of the present invention, X2, X3, X4, X5, X6, X7, X8 and X9 are selected from any one of the following combinations:

[0119]

[0120]

[0121] In some alternative embodiments of the present invention, the HCDRs and LCDRs are defined by a combination of the Kabat and AbM systems.

[0122] For example, HCDR 1 is defined by the AbM system, and HCDR 2, HCDR 3, LCDR 1, LCDR 2 and LCDR 3 are defined by the Kabat system.

[0123] In some optional embodiments of the present invention, the HCDRs and LCDRs have the following amino acid sequences:

[0124] HCDR 1:GYTFX1X2YVLH, where X1 is T or N, and X2 is I or L;

[0125] HCDR 2:YINPYIDX3TKYNEKFX4G, where X3 is G or R, and X4 is K or G;

[0126] HCDR 3:SGX5GX6YGLAWLAX7, where X5 is Y, M, I or T, X6 is N or P, and X7 is Y, I, H or M;

[0127] LCDR 1:RSSTGAVTTSNYAN;

[0128] LCDR 2:GSNNRAP;

[0129] LCDR 3:ALX8YX9NNWV, where X8 is V or L, and X9 is S or M.

[0130] In some optional embodiments of the present invention, X1 is T, X2 is I, X3 is G, X4 is K, X5 is Y, X6 is N, X7 is Y, X8 is V, and X9 is S may not coexist.

[0131] In some alternative embodiments of the present invention, X1 is T.

[0132] In some alternative embodiments of the present invention, X1 is N.

[0133] In some alternative embodiments of the present invention, X2 is I.

[0134] In some optional embodiments of the present invention, X2 is L;

[0135] In some alternative embodiments of the present invention, X3 is G.

[0136] In some alternative embodiments of the present invention, X3 is R.

[0137] In some alternative embodiments of the present invention, X4 is K.

[0138] In some optional embodiments of the present invention, X4 is G;

[0139] In some alternative embodiments of the present invention, X5 is Y.

[0140] In some alternative embodiments of the present invention, X5 is M.

[0141] In some alternative embodiments of the present invention, X5 is I.

[0142] In some alternative embodiments of the present invention, X5 is T.

[0143] In some alternative embodiments of the present invention, X6 is N.

[0144] In some alternative embodiments of the present invention, X6 is P.

[0145] In some alternative embodiments of the present invention, X7 is Y.

[0146] In some alternative embodiments of the present invention, X7 is I.

[0147] In some alternative embodiments of the present invention, X7 is H.

[0148] In some alternative embodiments of the present invention, X7 is M.

[0149] In some alternative embodiments of the present invention, X8 is V.

[0150] In some alternative embodiments of the present invention, X8 is L.

[0151] In some alternative embodiments of the present invention, X9 is S.

[0152] In some alternative embodiments of the present invention, X9 is M.

[0153] According to an embodiment of the present invention, X1, X2, X3, X4, X5, X6, X7, X8 and X9 are selected from any one of the following combinations:

[0154]

[0155]

[0156]

[0157] According to embodiments of the present invention, it further includes at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, and LFR4.

[0158] Wherein, at least a portion of at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, and LFR4 is derived from at least one of mouse antibodies, human antibodies, primate antibodies, bovine antibodies, equine antibodies, dairy bovine antibodies, porcine antibodies, sheep antibodies, goat antibodies, canine antibodies, feline antibodies, rabbit antibodies, camel antibodies, donkey antibodies, deer antibodies, mink antibodies, chicken antibodies, duck antibodies, goose antibodies, turkey antibodies, fighting rooster antibodies, or mutants thereof.

[0159] In this article, the "frame region" or "FR" region includes the heavy chain frame region and the light chain frame region, which refers to the region in the antibody heavy chain variable region (which can be represented as VH) and light chain variable region (which can be represented as VL) excluding the CDR. The heavy chain frame region is represented by "HFR" and can be further subdivided into adjacent regions separated by CDR, including the HFR1, HFR2, HFR3 and HFR4 frame regions; the light chain frame region is represented by "LFR" and can be further subdivided into adjacent regions separated by CDR, including the LFR1, LFR2, LFR3 and LFR4 frame regions.

[0160] As used herein, the heavy chain variable region is obtained by connecting the following numbered CDRs and FRs in the following combination: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by connecting the following numbered CDRs and FRs in the following combination: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.

[0161] According to an embodiment of the present invention, the HCDRs and LCDRs are defined by the Kabat system.

[0162] According to embodiments of the present invention, HFR1 comprises an amino acid sequence as shown in SEQ ID NO:94 or an amino acid sequence having at least 80% homology therewith; HFR2 comprises an amino acid sequence as shown in SEQ ID NO:10 or an amino acid sequence having at least 80% homology therewith; HFR3 comprises an amino acid sequence as shown in SEQ ID NO:11 or an amino acid sequence having at least 80% homology therewith; HFR4 comprises an amino acid sequence as shown in SEQ ID NO:12 or an amino acid sequence having at least 80% homology therewith; LFR1 comprises an amino acid sequence as shown in SEQ ID NO:13 or an amino acid sequence having at least 80% homology therewith; LFR2 comprises an amino acid sequence as shown in SEQ ID NO:14 or an amino acid sequence having at least 80% homology therewith; LFR3 comprises an amino acid sequence as shown in SEQ ID NO:15 or an amino acid sequence having at least 80% homology therewith; and LFR4 comprises an amino acid sequence as shown in SEQ ID NO:16 or an amino acid sequence having at least 80% homology therewith.

[0163] According to an embodiment of the present invention, HCDR 1 is defined by the AbM system, and HCDR 2, HCDR 3, LCDR 1, LCDR 2 and LCDR 3 are defined by the Kabat system.

[0164] According to embodiments of the present invention, HFR1 comprises an amino acid sequence as shown in SEQ ID NO:9 or an amino acid sequence having at least 80% homology therewith; HFR2 comprises an amino acid sequence as shown in SEQ ID NO:10 or an amino acid sequence having at least 80% homology therewith; HFR3 comprises an amino acid sequence as shown in SEQ ID NO:11 or an amino acid sequence having at least 80% homology therewith; HFR4 comprises an amino acid sequence as shown in SEQ ID NO:12 or an amino acid sequence having at least 80% homology therewith; LFR1 comprises an amino acid sequence as shown in SEQ ID NO:13 or an amino acid sequence having at least 80% homology therewith; LFR2 comprises an amino acid sequence as shown in SEQ ID NO:14 or an amino acid sequence having at least 80% homology therewith; LFR3 comprises an amino acid sequence as shown in SEQ ID NO:15 or an amino acid sequence having at least 80% homology therewith; and LFR4 comprises an amino acid sequence as shown in SEQ ID NO:16 or an amino acid sequence having at least 80% homology therewith.

[0165] According to an embodiment of the present invention, the antibody includes the heavy chain variable region and / or the light chain variable region described in the first aspect.

[0166] According to embodiments of the present invention, the antibodies described in the first and second aspects above may further include at least one of the following technical features:

[0167] According to an embodiment of the present invention, the antibody further includes a constant region; wherein the constant region includes at least one of a heavy chain constant region and a light chain constant region.

[0168] According to embodiments of the present invention, at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of mouse antibodies, human antibodies, primate antibodies, bovine antibodies, equine antibodies, dairy bovine antibodies, porcine antibodies, sheep antibodies, goat antibodies, canine antibodies, feline antibodies, rabbit antibodies, camel antibodies, donkey antibodies, deer antibodies, mink antibodies, chicken antibodies, duck antibodies, goose antibodies, turkey antibodies, fighting rooster antibodies, or mutants thereof.

[0169] According to embodiments of the present invention, the heavy chain constant region includes a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; or, the light chain constant region includes a light chain constant region selected from κ-type or λ-type.

[0170] In an optional embodiment of the present invention, both the light chain constant region and the heavy chain constant region are derived from mouse antibodies or their mutants.

[0171] In an optional embodiment of the present invention, the heavy chain constant region includes or is an amino acid sequence as shown in SEQ ID NO:17 or having at least 80% identity with it; or the light chain constant region includes or is a light chain constant region as shown in SEQ ID NO:18 or having at least 80% identity with it.

[0172] According to an embodiment of the present invention, the N end of the heavy chain constant region is connected to the C end of the heavy chain variable region, and the N end of the light chain constant region is connected to the C end of the light chain variable region.

[0173] In this paper, the partitioning of the variable and constant regions is based on the IMGT partitioning method, see Lefranc, M. the international ImMunoGeneTics database.Nucl.Acids Res.,29(1):207-209(2001).DOI:10.1093 / nar / 29.1.207.PMID:11125093.and Martinez-Jean C.and BoscN.or Ehrenmann,Patrice Duroux,Chantal Ginestoux,Gene table:house mouse(Mus musculus)IGHC,IMGT Repertoire. the international ImMunoGeneticsinformation http: / / www.imgt.org.Created:16 / 03 / 2011.Version:17 / 01 / 2020.or Ehrenmann,Patrice Duroux,Chantal Ginestoux,Gene table:house mouse(Musmusculus)IGLC,IMGT Repertoire. the international ImMunoGeneticsinformation http: / / www.imgt.org.Created:16 / 03 / 2011.Version:17 / 01 / 2020. The variable regions delineated by different methods may differ in some amino acids from the C-terminus of the variable region or the N-terminus of the constant region delineated by IMGT. Variable regions or constant regions delineated by other methods known in the art are also within the scope of protection of this invention.

[0174] In an optional embodiment of the invention, the heavy chain and the light chain are selected from any combination of the following:

[0175]

[0176]

[0177]

[0178] Those skilled in the art will understand that the features and advantages described above with respect to the first aspect of the antibody also apply to the antibody described in the second aspect, and will not be repeated here.

[0179] According to embodiments of the present invention, the antibody comprises at least one selected from polyclonal antibodies, full-length monoclonal antibodies, Fab antibodies, Fab' antibodies, F(ab')2 antibodies, Fv antibodies, single-chain antibodies, single-domain antibodies, and minimal recognition units; or, the functional fragment comprises at least one selected from F(ab')2 fragments, Fab' fragments, Fab fragments, F(ab)2 fragments, Fv fragments, scFv fragments, scFv-Fc fusion proteins, scFv-Fv fusion proteins, and minimal recognition units.

[0180] It should be noted that "functional fragment" refers to a fragment that maintains the ability to specifically bind to cTnI, including but not limited to Fv fragments, disulfide bond-stabilized Fv fragments (dsFv), F(ab')2 fragments, Fab' fragments, Fab fragments, F(ab)2 fragments, scFv fragments, scFv-Fc fusion proteins, scFv-Fv fusion proteins, Fv-Fc fusion proteins, multispecific antibodies formed from functional fragments, single-domain antibodies, VHH nanobodies, domain antibodies, bivalent domain antibodies, or at least one of the smallest recognition units.

[0181] In this paper, the terms “single-domain antibody,” “nanobody,” and “VHH antibody” are used interchangeably. The antibody was originally described as an antigen-binding immunoglobulin (variable) domain of a “heavy chain antibody” (i.e., “antibody lacking light chains”) containing a heavy chain variable region (VH) and conventional CH2 and CH3 regions, which specifically binds to antigen proteins (e.g., cTnI) through the heavy chain variable region.

[0182] In this article, the term "Fab antibody" or "Fab fragment" generally refers to an antibody or fragment containing only Fab molecules, which consists of the VH and CH1 of the heavy chain and the complete light chain, linked by a disulfide bond.

[0183] In this paper, the term “F(ab')2 antibody” or “F(ab')2 fragment” has two antigen-binding F(ab') parts linked together by disulfide bonds.

[0184] In this article, the term "Fv antibody" or "Fv fragment" generally refers to an antibody or fragment consisting only of a light chain variable region (VL) and a heavy chain variable region (VH) linked by non-covalent bonds. It is the smallest functional fragment of an antibody that retains the complete antigen-binding site.

[0185] In this paper, the terms "single-chain antibody" and "scFv fragment" refer to antibodies or fragments formed by linking the variable regions of the antibody heavy chain and light chain through short peptides.

[0186] In this article, the terms "minimum recognition unit" and "MRU" both refer to antibodies or fragments consisting of only one CDR, with a very small molecular weight, accounting for only about 1% of a complete antibody.

[0187] Nucleic acid molecules, vectors, cells or hosts, and methods for preparing antibodies.

[0188] In the process of preparing or obtaining the antibodies described in the first or second aspect, nucleic acid molecules expressing these antibodies can be linked to different vectors and then expressed in different cells to obtain the corresponding antibodies.

[0189] In a third aspect, the present invention provides a nucleic acid molecule. According to embodiments of the present invention, the nucleic acid molecule encodes the antibody described in the first or second aspect. The nucleic acid molecule according to embodiments of the present invention can encode the aforementioned antibody.

[0190] According to embodiments of the present invention, the nucleic acid molecule includes DNA or RNA.

[0191] It should be noted that those skilled in the art will understand that the nucleic acid molecules mentioned herein actually include any one or both of the complementary double strands. For convenience, although only one strand is given in most cases, the complementary strand is also disclosed. Furthermore, the molecular sequences in this invention include DNA or RNA forms; disclosure of one implies that the other is also disclosed.

[0192] In a fourth aspect, the present invention provides a vector. According to embodiments of the present invention, the vector comprises the nucleic acid molecule described in the third aspect. When the above-mentioned nucleic acid molecule is ligated to the vector, the nucleic acid molecule can be directly or indirectly linked to control elements on the vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can be directly derived from the vector itself or can be exogenous, i.e., not derived from the vector itself. Of course, the nucleic acid molecule and the control elements can be operably linked. In this document, "operably linked" means ligating a foreign gene to the vector so that the control elements within the vector, such as transcription control sequences and translation control sequences, can perform their intended functions of regulating the transcription and translation of the foreign gene. Commonly used vectors can be, for example, plasmids, bacteriophages, etc. After the vector of some specific embodiments of the present invention is introduced into suitable recipient cells, the aforementioned antibody expression can be effectively achieved under the mediation of a regulatory system, thereby achieving large-scale in vitro production of antibodies.

[0193] In some specific embodiments of the present invention, the vector is a eukaryotic expression vector, a prokaryotic expression vector, a virus, or a bacteriophage.

[0194] In an optional embodiment of the present invention, the expression vector is a plasmid expression vector.

[0195] In a fifth aspect, the present invention provides a cell or host. According to embodiments of the invention, the cell or host comprises: the nucleic acid molecule described in the third aspect or the vector described in the fourth aspect; or expressing the antibody described in the first or second aspect. Using this cell, under suitable conditions, the aforementioned antibody can be efficiently expressed intracellularly.

[0196] According to an embodiment of the present invention, the cell is obtained by introducing the carrier described in the fourth aspect into the cell.

[0197] It should be noted that the cells used in this invention are not particularly limited and can be prokaryotic cells, eukaryotic cells, or bacteriophages. The prokaryotic cells can be Escherichia coli, Bacillus subtilis, Streptomyces, or Proteus mirabilis, etc. The eukaryotic cells include fungi such as Pichia pastoris, Saccharomyces cerevisiae, Schizosoma, and Trichoderma; insect cells such as armyworms; plant cells such as tobacco; and mammalian cells such as BHK cells, CHO cells, COS cells, and myeloma cells.

[0198] In an optional embodiment of the present invention, the cells are mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, but do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0199] It should be noted that the "suitable conditions" mentioned in this invention refer to conditions suitable for the expression of the antibody described in this invention. Those skilled in the art will readily understand that suitable conditions for antibody expression include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy cell state, suitable cell density, suitable cell culture environment, and suitable cell culture time. The term "suitable conditions" is not particularly limited, and those skilled in the art can optimize the optimal conditions for antibody expression based on the specific environment of their laboratory.

[0200] In a sixth aspect, the present invention provides a method for preparing the antibodies described in the first or second aspect. According to embodiments of the invention, the method includes culturing the cells or host described in the fifth aspect. The methods according to some specific embodiments of the invention can efficiently obtain large quantities of the antibodies.

[0201] Based on the amino acid sequence of the antibody disclosed herein, those skilled in the art will readily conceive of preparing the antibody using genetic engineering or other techniques (chemical synthesis, recombinant expression), such as isolating and purifying the antibody from the culture product of recombinant cells capable of recombinantly expressing the antibody as described in any of the preceding claims. This is easily achievable by those skilled in the art. Therefore, regardless of the technique used to prepare the antibody disclosed herein, it falls within the protection scope of this disclosure.

[0202] Those skilled in the art will understand that the features and advantages described above with respect to the first and second aspects of the antibody also apply to the nucleic acid molecule, vector, cell or host, and the method of preparing the antibody, and will not be repeated here.

[0203] Conjugates, reagents or kits and their uses

[0204] In a seventh aspect, the present invention provides a conjugate. According to embodiments of the invention, the conjugate comprises: the antibody described in the first or second aspect and a conjugation portion thereto. The conjugate according to embodiments of the invention can specifically bind to cTnI and can be used for qualitative or quantitative detection of cTnI, or for diagnosing cTnI-related diseases.

[0205] According to embodiments of the present invention, the above-mentioned coupling may further include at least one of the following additional technical features:

[0206] According to an embodiment of the present invention, the coupling portion includes at least one of a purification tag, an affinity substance, a marker, and a solid-phase support.

[0207] According to an embodiment of the present invention, the purification label includes at least one of the following: His label, Flag label, GST label, MBP label, SUMO label, and C-Myc label.

[0208] In this document, the affinity substance may be, for example, biotin, biotin derivatives or streptavidin, one of the complementary sense and antisense strands of nucleic acids.

[0209] In some alternative embodiments of the present invention, the affinity substance includes at least one selected from biotin, biotin derivatives, or streptavidin.

[0210] In this article, "marker" refers to a class of substances that have properties that can be directly observed by the naked eye or detected or probing by instruments, such as luminescence, color development, radioactivity, etc., which enable qualitative or quantitative detection of the corresponding target.

[0211] According to embodiments of the present invention, the marker includes at least one selected from fluorescent dyes, enzymes, radioisotopes, chemiluminescent reagents, and nanoparticle markers.

[0212] In practical use, those skilled in the art can select appropriate markers according to the detection conditions or actual needs. Regardless of the marker used, it falls within the protection scope of this invention.

[0213] According to embodiments of the present invention, the fluorescent dyes include, but are not limited to, fluorescein dyes and their derivatives (e.g., including but not limited to fluorescein isothiocyanate (FITC), hydroxyfluorescein (FAM), tetrachlorofluorescein (TET), etc., or their analogues), rhodamine dyes and their derivatives (e.g., including but not limited to red rhodamine (RBITC), tetramethylrhodamine (TAMRA), rhodamine B (TRITC), etc., or their analogues), and Cy series dyes and their derivatives (e.g., including but not limited to Cy2, Cy3, Cy3B, Cy3.5, C...). y5, Cy5.5, Cy3 and other similar substances), Alexa series dyes and their derivatives (including but not limited to Alexa Fluor 350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750 and other similar substances) and protein dyes and their derivatives (including but not limited to phycoerythrin (PE), phycocyanin (PC), allophycocyanin (APC), polydiophytoxanthin-chlorophyll protein (preCP) and other similar substances).

[0214] According to embodiments of the present invention, the enzymes include, but are not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose-6-phosphate deoxygenase.

[0215] According to embodiments of the present invention, the radioactive isotopes include, but are not limited to, those mentioned above. 212 Bi、 131 I, 111 In、 90 Y、 186 Re、 211 At、 125 I, 188 Re、 153 Sm、 213 Bi、 32 P, 94 mTc, 99 mTc, 203 Pb, 67 Ga、 68 Ga、 43 Sc、 47 Sc、 110 mIn, 97 Ru、 62 Cu、 64 Cu、 67 Cu、 68 Cu、 86 Y、 88 Y、 121 Sn、 161 Tb, 166 Ho、 105 Rh、177 Lu、 172 Lu and 18 F.

[0216] According to embodiments of the present invention, the chemiluminescent reagents include, but are not limited to, luminol and its derivatives, luciferin, fluorescein and its derivatives, ruthenium bipyridine and its derivatives, acridine ester and its derivatives, dioxane and its derivatives, rofenine and its derivatives, and peroxazone and its derivatives.

[0217] According to embodiments of the present invention, the nanoparticle-based markers include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.

[0218] According to embodiments of the present invention, the colloid includes, but is not limited to, colloidal metals, dispersed dyes, dye-labeled microspheres, and latexes.

[0219] According to embodiments of the present invention, the colloidal metal includes, but is not limited to, colloidal gold, colloidal silver, and colloidal selenium.

[0220] In this document, the solid support can be a substance that can be suspended or dispersed in a liquid phase (e.g., solid supports such as particles and magnetic beads), or a solid phase that can contain or carry a liquid phase (e.g., supports such as plates, membranes, and test tubes, as well as containers such as perforated plates, microfluidic paths, glass capillaries, nanopillars, and monolithic columns).

[0221] According to an embodiment of the present invention, the solid support comprises at least one selected from microspheres, plates, and membranes.

[0222] In an eighth aspect, the present invention provides a reagent or kit. According to embodiments of the present invention, the reagent or kit comprises: the antibody described in the first or second aspect or the conjugate described in the seventh aspect. As previously mentioned, the antibodies in some specific embodiments or examples of the present invention are capable of binding to cTnI; therefore, reagents or kits containing said antibodies can effectively perform qualitative or quantitative detection of cTnI. The reagents or kits provided by the present invention can be used, for example, for detections involving the specific binding properties of cTnI and its antibodies, such as immunoblotting and immunoprecipitation. As previously mentioned, the antibodies of the present invention have higher cTnI binding activity, affinity, stability, or specificity; therefore, reagents or kits containing said antibodies have higher detection sensitivity or specificity.

[0223] The above kit may contain any one or more of the following: processing solution, anti-cTnI antibody, cTnI quality control, anti-IgG antibody, instructions for use, or literature. Anti-cTnI antibodies can be used for various types of diagnostic tests, such as detecting the presence of various diseases, drugs, or other proteins in vitro or in vivo. For example, they can be used to test for related diseases by detecting the serum or blood of a subject.

[0224] In a ninth aspect of the invention, the invention provides the use of an antibody as described in the first or second aspect, a conjugate as described in the seventh aspect, or a reagent or kit as described in the eighth aspect in detecting cTnI, diagnosing cTnI-related diseases, preparing products for detecting cTnI, or preparing products for diagnosing cTnI-related diseases.

[0225] According to embodiments of the present invention, the cTnI-related diseases include myocardial necrosis, myocardial injury, acute myocardial infarction, and acute coronary syndrome.

[0226] In a tenth aspect of the invention, a method for detecting cTnI is provided. According to an embodiment of the invention, the method includes: contacting a sample to be tested with an antibody described in the first or second aspect, a conjugate described in the seventh aspect, or a reagent or kit described in the eighth aspect to form an immune complex.

[0227] It should be noted that the "sample to be tested" mentioned above can be a patient's sample, such as serum; or it can be a non-patient sample that may contain cTnI. For example, in scientific research, the above method is only used to detect the presence or content of cTnI in the sample and does not involve disease diagnosis.

[0228] According to an embodiment of the present invention, the presence of cTnI or the content of cTnI in the sample to be tested is determined based on the signal of the immune complex.

[0229] According to an embodiment of the present invention, the immune complex further includes a second antibody, which binds to the antibody.

[0230] According to an embodiment of the present invention, the immune complex further includes a second antibody, which binds to cTnI.

[0231] According to an embodiment of the present invention, the signal includes a fluorescence signal.

[0232] Methods, Mutant Library

[0233] In an eleventh aspect of the present invention, a method for screening cTnI antibodies is provided. According to an embodiment of the present invention, the method includes: a) designing primers for amino acid substitution at one, two, three, four, five, six, seven, or eight sites selected from X2, X3, X4, X5, X6, X7, X8, and X9 in the antibody described in the first aspect; or for amino acid substitution at one, two, three, four, five, six, seven, eight, or nine sites selected from X1, X2, X3, X4, X5, X6, X7, X8, and X9 in the antibody described in the first aspect;

[0234] b) A mutant library constructed using the primers described in a) with the nucleic acid molecules described in the third aspect, the vector described in the fourth aspect, or the cell described in the fifth aspect as templates;

[0235] c) Screen for cTnI antibodies from the mutant library.

[0236] According to an embodiment of the present invention, the mutant library is a single-point saturation mutant library.

[0237] According to embodiments of the present invention, the cTnI antibody includes or is the antibody described in the first or second aspect.

[0238] In a twelfth aspect of the invention, the invention provides a mutant library comprising the antibody described in the first or second aspect.

[0239] According to an embodiment of the present invention, the mutant library is obtained by the method described in the eleventh aspect.

[0240] In a thirteenth aspect of the invention, a method for diagnosing cTnI-related diseases is provided. According to embodiments of the invention, the method includes: contacting a sample to be tested from a subject with an antibody described in the first or second aspect, a conjugate described in the seventh aspect, or a reagent or kit described in the eighth aspect to form an immune complex.

[0241] According to an embodiment of the present invention, the presence or absence of CTNI-related disease in the subject is indicated based on the signal of the immune complex.

[0242] In a fourteenth aspect, the present invention provides a method for assessing the prognosis of cTnI-related diseases. According to embodiments of the invention, the method comprises: contacting a sample to be tested from a subject with an antibody described in the first or second aspect, a conjugate described in the seventh aspect, or a reagent or kit described in the eighth aspect to form an immune complex.

[0243] According to an embodiment of the present invention, the prognosis or treatment effect of the subject's CTNI-related disease is indicated based on the signal of the immune complex.

[0244] According to embodiments of the present invention, the methods described in the thirteenth and fourteenth aspects above may further include at least one of the following technical features:

[0245] According to an embodiment of the present invention, the immune complex further includes a second antibody, which binds to the antibody.

[0246] According to an embodiment of the present invention, the immune complex further includes a second antibody, which binds to cTnI.

[0247] According to an embodiment of the present invention, the signal includes a fluorescence signal.

[0248] As used herein, the term "subject" refers to a vertebrate, preferably a mammal, and most preferably a human. Mammals include, but are not limited to, rodents, apes, humans, livestock, racing animals, and pets. Tissues, cells, and their progeny from biological entities obtained in vivo or cultured in vitro are also included.

[0249] The amino acid sequences involved in this article are shown in Table 2:

[0250] Table 2: Amino Acid Sequences

[0251]

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265] The present invention will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.

[0266] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. While any methods and materials similar to or equivalent to those described herein may be used in the practice or testing of formulations or unit doses herein, some methods and materials are described hereby. Unless otherwise stated, the techniques employed or considered herein are standard methods. Materials, methods, and examples are illustrative and not limiting in nature.

[0267] Unless otherwise specified, the practice of this disclosure will employ conventional techniques of cell biology, molecular biology (including recombinant technologies), microbiology, biochemistry, and immunology, which are within the capabilities of those skilled in the art. This technique is well explained in the literature, such as *Molecular Cloning: A Laboratory Manual*, 2nd edition (Sambrook et al., 1989); *Oligonucleotide Synthesis* (edited by M.J. Gait, 1984); *Animal Cell Culture* (edited by R.R. Freshney, 1987); *Methods in Enzymology* (Academic Press, Inc.); *Handbook of Experimental Immunology* (edited by D.M. Weir and C.C. Blackwell); *Gene Transfer Vectors for Mammalian Cells* (edited by J.M. Miller and M.P. Calos, 1987); *Current Protocols in Molecular Biology* (edited by F.M. Mausubel et al., 1987); and *PCR: The Polymerase Chain Reaction*. The references cited in the references are: "Reaction" (Mullis et al., ed., 1994) and "Current Protocols in Immunology" (JEColigan et al., ed., 2011), each of which is explicitly incorporated herein by reference.

[0268] In this embodiment, restriction endonucleases, T4 DNA ligase, and DNA polymerase were purchased from New England Biolabs, Taq DNA polymerase was purchased from TaKaRa, gel extraction kits and plasmid extraction kits were commercially available, and primer synthesis and gene sequencing were outsourced. The cTnI monoclonal antibody (hereinafter referred to as WT antibody) sequence was obtained from mouse hybridoma cell sequencing.

[0269] Example 1: Construction and screening of mutant libraries

[0270] 1. Construction of template plasmid for wild-type (WT) cTnI antibody (WT antibody for short)

[0271] (1) WT antibody gene synthesis:

[0272] The nucleotide sequences of VH and VL of the WT antibody were optimized using E. coli codons, and then the antibody gene sequence was synthesized. The amino acid sequences of VH and VL of the WT antibody are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively, and the amino acid sequences of the heavy chain and light chain are shown in SEQ ID NO:19 and SEQ ID NO:20, respectively. (2) Amplification of WT antibody gene fragment:

[0273] The nucleotide sequences of antibodies VH and VL synthesized in step (1) were amplified by DNA polymerase PCR, and then the antibody bands were separated by agarose gel electrophoresis. The antibody gene fragments were then purified using a gel recovery kit.

[0274] (3) Enzyme digestion and ligation of WT antibody gene fragments:

[0275] The antibody gene fragment and the VO1 vector plasmid (including the nucleotide sequence of the constant region) obtained in step (2) were simultaneously digested with restriction endonucleases. The resulting antibody gene fragment and VO1 vector with sticky ends were then purified using a gel extraction kit. Next, the antibody gene fragment and VO1 vector were ligated with T4 DNA ligase at 22°C for 4 hours. The ligation product was then recovered and purified, and the DNA concentration was determined. Finally, 100 ng of the plasmid was transformed into 100 μl of TG1 E. coli competent cells to obtain a bacterial culture. The entire bacterial culture was then plated onto ampicillin-resistant plates and incubated overnight at 37°C.

[0276] (4) Extraction and sequencing verification of WT template plasmid

[0277] Ten single-clone colonies were selected from the overnight culture in step (3). Colony PCR and gel electrophoresis were performed using Taq DNA polymerase. The bacteria with the correct inserted antibody gene sequence were selected for culture and amplification. The plasmid was extracted using a plasmid extraction kit and then sent to a sequencing company for gene sequencing verification.

[0278] 2. Construction of single-point mutation libraries

[0279] This part of the experiment involves performing single-point saturation mutations on the VH and VL full CDR regions of the WT antibody obtained in step 1 to construct a single-point mutation library.

[0280] (1) Primer design and synthesis

[0281] Using degenerate base codons, single-point saturation mutation upstream and downstream primer pairs for amino acid sites in the VH and VL full CDR regions were designed, and the primer synthesis was outsourced to a company.

[0282] (2) PCR amplification of single-point saturation mutant plasmid

[0283] Using the primers obtained in step (1), the single-point saturated mutant plasmid was amplified by PCR. The reaction system was prepared according to Table 3, and then the PCR reaction conditions in Table 4 were used to amplify and prepare the single-point saturated mutant library plasmid. Finally, the WT template plasmid obtained in step 1 was digested with restriction endonuclease at 37°C for 1 hour to obtain the plasmid of the mutant library with all CDR amino acid sites.

[0284] Table 3: PCR amplification reaction system

[0285] WT template plasmid 50ng DNA polymerase 1μl DNA polymerase buffer 10μl dNTP (2.5mM) 4μl Upstream primer (10 μM) 1μl Downstream primer (10 μM) 1μl ddH2O Adjust the volume to 50 μl

[0286] Table 4: PCR reaction conditions

[0287] Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 temperature 95℃ 95℃ 55-60℃ 72℃ 72℃ 4℃ time 5min 30s 30s 2min 5min ∞

[0288] Note: Steps 2 through 4 are repeated 22 times.

[0289] (3) Transformation with single-point saturation mutant plasmids:

[0290] Take 10 μl of the plasmids of the mutant library of amino acid sites in the full CDR region obtained in step (2), transform 10 μl of each reaction product into 100 μl of TG1 Escherichia coli competent cells to obtain bacterial culture, and then spread all the bacterial culture on a plate containing ampicillin resistance and incubate overnight at 37°C.

[0291] 3. Screening of single-point mutation libraries

[0292] (1) Antibody expression in mutant library

[0293] 500 μl of culture medium was added to a 96-well plate beforehand. For each single-point mutation library, 92 single-clone colonies transformed from the single-point saturated mutant plasmids cultured overnight in step 2-(3) were selected. WT, negative control (i.e., colonies without the insertion of VH / VL genes), and blank control (i.e., only culture medium, no colonies) colonies were set up. After culturing at 37°C for 5-6 hours, the bacterial culture was transferred to a new 96-well plate. After culturing at 37°C for 1-2 hours, induction medium was added, and the plate was cultured overnight at 37°C to express antibodies, thus obtaining the antibody expression supernatant of the mutant library with all CDR amino acid sites.

[0294] (2) Mutant library screening and sequencing

[0295] Commercially available cTnI protein was added to ELISA plates at a rate of 0.0032 μg / ml and 100 μl / well. The plates were incubated overnight at 4°C. The plates were then blocked with 1-2% skim milk powder the next day. The antibody expression supernatant of the mutant library obtained in step (1) was added to the wells of the ELISA plates at a rate of 100 μl / well. WT, negative control (i.e., colonies without VH / VL genes) and blank control (i.e., only culture medium without colonies) were set up and incubated at room temperature for 2 hours. The plates were washed, developed, and read using the conventional ELISA detection method. Finally, the data results were sorted and analyzed. Clones with improved mutations were sent for sequencing. The sequencing results were analyzed, and the mutation sites of 13 unique mutant candidate clones were selected (see Table 5) for the construction of combined mutant libraries. (The Ratio values ​​in Table 5 represent the degree of affinity enhancement. When the Ratio value is equal to 1, it means that the affinity of the mutant clone is the same as that of WT; when the Ratio value is greater than 1, it means that the affinity has been enhanced.)

[0296] Table 5: Screening results and mutation sites of candidate clones

[0297]

[0298] Note: In this paper, WT represents no mutation relative to the wild-type sequence (same as Table 6 and Table 7); the positions of the mutated amino acids in this paper are obtained by sequentially numbering the amino acid sequences of VH or VL of WT from the N-terminus to the C-terminus.

[0299] 4. Construction of combined mutant libraries

[0300] (1) Library primer design and synthesis:

[0301] Based on the mutation sites on VH and VL of the cTnI antibody obtained in step 3-(2), amplification primers for the combined mutant library were designed and primers were synthesized.

[0302] (2) Fragment amplification and ligation

[0303] According to the PCR system in Table 3 and the PCR reaction conditions in Table 4, the antibody mutant fragments were amplified, and then the antibody mutant fragments were recovered by gel electrophoresis. The antibody mutant fragments were then spliced ​​into complete antibody fragments (heavy chain variable region or light chain variable region) using the overlap PCR method.

[0304] Finally, the antibody fragment was inserted into the V01 vector by enzyme digestion and ligation to form a complete antibody expression plasmid (see step 1-(3) "WT antibody gene fragment digestion and ligation" for specific steps). 100 ng of plasmid was transformed into 100 μl of TG1 Escherichia coli competent cells, and the entire bacterial culture was plated on an ampicillin-resistant plate and incubated overnight at 37°C.

[0305] 5. Screening of combined mutant libraries

[0306] Sixty-four randomly selected combined mutant antibodies were expressed, screened by ELISA, and analyzed by sequencing of positive clones. Mutation site information and ratio values ​​are shown in Table 6.

[0307] Table 6: Information on candidate clones with combined mutations

[0308]

[0309]

[0310]

[0311] Example 2: Expression of mutant cTnI antibody

[0312] This embodiment expresses the mutant cTnI antibody obtained in Example 1. The specific experimental procedures are as follows:

[0313] 1. Construction of eukaryotic recombinant expression plasmids

[0314] pcDNA TM 3.4 The vector is a recombinant antibody eukaryotic expression vector constructed. This expression vector has been introduced with multiple cloning restriction sites such as HindIII, BamHI, and EcoRI, and is named pcDNA3.4A expression vector, hereinafter referred to as 3.4A expression vector. Based on the variable region gene sequences in the candidate clones screened in Example 1, VL and VH gene-specific amplification primers and constant region overlap primers for the corresponding antibody sequences were designed. The primers at both ends are equipped with HindIII and EcoRI restriction sites and protective bases, respectively. A 0.73kb light chain gene fragment and a 1.40kb heavy chain gene fragment were amplified by PCR.

[0315] Heavy and light chain gene fragments were double-digested with HindIII / EcoRI, and the 3.4A vector was also double-digested with HindIII / EcoRI. The digested antibody light and heavy chain gene fragments and the vector were purified and recovered. The gene fragments encoding the antibody light and heavy chains were then ligated into the 3.4A expression vector and transformed into DH5α *E. coli* competent cells. After growth, single colonies were picked for PCR identification of positive clones. Positive clones were sequenced to confirm sequence accuracy. Plasmids were extracted from correctly sequenced clones for later use.

[0316] 2. Sample preparation of recombinant antibodies

[0317] HEK293 cells were revived early and passaged to a 200ml volume to achieve a cell density of (3-5)×10⁻⁶ cells / mL. 6 Cells / ml, cell viability >95%; centrifuge to wash cells, rehydrate with culture medium, and adjust cell density to 2.9 × 10⁶ cells / ml. 6 Cells / ml were used as cell dilution buffers. Plasmid DNA and transfection reagent dilution buffers were prepared separately using culture medium. The transfection reagent dilution buffer was added to the plasmid DNA dilution buffer, mixed well, and incubated at room temperature for 15 min. This mixture was then slowly added to the cell dilution buffer over 1 min, mixed well, and samples were taken for counting. Cell viability after transfection was recorded and observed. The cells were then incubated at 35°C with a rotation speed of 120 rpm and a CO2 concentration of 8%. After 13 days, the samples were centrifuged and collected. Seventy-seven antibodies were obtained through affinity purification using a protein A affinity chromatography column. The amino acid sequences of the heavy and light chains of the 77 antibodies are shown in Table 7.

[0318] Table 7: Amino acid sequences of the heavy and light chains of 77 antibodies

[0319]

[0320]

[0321]

[0322] Example 3: Affinity Analysis

[0323] The wild-type antibody (WT) and the mutant antibody prepared in Example 2 were subjected to affinity testing and analysis. The specific steps were as follows: the binding and dissociation curves of cTnI and the cTnI antibody were tested on a Biacore 8K+ instrument. The instrument automatically fitted and obtained the affinity constant, binding rate, and dissociation rate. In the affinity test results, KD represents the equilibrium dissociation constant, i.e., the affinity constant; the smaller the KD value, the higher the affinity; ka represents the binding rate; and kd represents the dissociation rate. The results showed that the affinity between the mutant antibody and cTnI was superior to that between the wild-type antibody and cTnI. The affinity test results of the antibodies are exemplarily shown in Table 8 below:

[0324] Table 8: Antibody Affinity Detection Results

[0325]

[0326]

[0327]

[0328] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., refer to specific features, structures, materials, or characteristics described in connection with that embodiment or example, which are included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0329] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. An anti-cTnI antibody, characterized in that, include: Heavy chain variable region and light chain variable region; The heavy chain variable region and the light chain variable region are selected from any combination of the following: The mutation sites are numbered sequentially from the N-end to the C-end using SEQ ID NO:1 or SEQ ID NO:

2.

2. An anti-cTnI antibody, comprising HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, characterized in that, The HCDR1, HCDR2, and HCDR3 are amino acid sequences identical to those of the heavy chain variable region defined by the antibody of claim 1; the LCDR1, LCDR2, and LCDR3 are amino acid sequences identical to those of the light chain variable region defined by the antibody of claim 1. The HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by any one of the systems Kabat, Chothia, IMGT, AbM, or Contact.

3. The antibody according to claim 2, characterized in that, According to the Kabat system definition, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 have the following amino acid sequences: HCDR 1:X2YVLH, where X2 is I or L; HCDR 2: YINPYIDX3TKYNEKFX4G, where X3 is G or R, and X4 is K or G; HCDR 3: SGX5GX6YGLAWLAX7, where X5 is Y, M, I or T, X6 is N or P, and X7 is Y, I, H or M; LCDR 1: RSSTGAVTTSNYAN; LCDR 2: GSNNRAP; LCDR 3: ALX8YX9NNWV, where X8 is L and X9 is S or M; X2, X3, X4, X5, X6, X7, X8, and X9 are selected from any of the following combinations: 。 4. The antibody according to claim 3, characterized in that, The antibodies further include HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, and LFR4; HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, and LFR4 are derived from mouse antibodies, primate antibodies, bovine antibodies, equine antibodies, porcine antibodies, sheep antibodies, goat antibodies, canine antibodies, feline antibodies, rabbit antibodies, camel antibodies, donkey antibodies, deer antibodies, mink antibodies, chicken antibodies, duck antibodies, goose antibodies, or mutants thereof.

5. The antibody according to claim 4, characterized in that, The HFR1 comprises an amino acid sequence that has at least 80% homology with the amino acid sequence shown in SEQ ID NO:9; The HFR2 comprises an amino acid sequence that has at least 80% homology with the amino acid sequence shown in SEQ ID NO:10; The HFR3 comprises an amino acid sequence having at least 80% homology with the amino acid sequence shown in SEQ ID NO:11; The HFR4 comprises an amino acid sequence that has at least 80% homology with the amino acid sequence shown in SEQ ID NO:12; The LFR1 comprises an amino acid sequence that has at least 80% homology with the amino acid sequence shown in SEQ ID NO:13; The LFR2 comprises an amino acid sequence that has at least 80% homology with the amino acid sequence shown in SEQ ID NO:14; The LFR3 comprises an amino acid sequence having at least 80% homology with the amino acid sequence shown in SEQ ID NO:15; The LFR4 comprises an amino acid sequence that has at least 80% homology with the amino acid sequence shown in SEQ ID NO:

16.

6. The antibody according to claim 5, characterized in that, The amino acid sequence of HFR1 is shown in SEQ ID NO:94; The amino acid sequence of HFR2 is shown in SEQ ID NO:10; The amino acid sequence of HFR3 is shown in SEQ ID NO:11; The amino acid sequence of HFR4 is shown in SEQ ID NO:12; The amino acid sequence of LFR1 is shown in SEQ ID NO:13; The amino acid sequence of the LFR2 is shown in SEQ ID NO:14; The amino acid sequence of the LFR3 is shown in SEQ ID NO:15; The amino acid sequence of LFR4 is shown in SEQ ID NO:

16.

7. The antibody according to any one of claims 1 to 6, characterized in that, The antibody further includes a constant region; The constant region includes at least one of the heavy chain constant region and the light chain constant region; At least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of mouse antibodies, primate antibodies, bovine antibodies, equine antibodies, porcine antibodies, sheep antibodies, goat antibodies, canine antibodies, feline antibodies, rabbit antibodies, camel antibodies, donkey antibodies, deer antibodies, mink antibodies, chicken antibodies, duck antibodies, goose antibodies, or mutants thereof.

8. The antibody according to claim 7, characterized in that, The heavy chain constant region is selected from the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD; or The light chain constant region is selected from the κ-type or λ-type light chain constant region.

9. The antibody according to claim 7, characterized in that, Both the light chain constant region and the heavy chain constant region are derived from murine antibodies or their mutants.

10. The antibody according to claim 7, characterized in that, The heavy chain constant region comprises an amino acid sequence having at least 80% identity with SEQ ID NO:17; or The light chain constant region includes an amino acid sequence that is at least 80% identical to SEQ ID NO:

18.

11. The antibody according to claim 10, characterized in that, The amino acid sequence of the heavy chain constant region is shown in SEQ ID NO: 17; or The amino acid sequence of the constant region of the light chain is shown in SEQ ID NO:

18.

12. The antibody according to claim 7, characterized in that, It includes heavy chains and light chains, wherein the heavy chains and light chains are selected from any combination of the following: 。 13. The antibody according to claim 1, characterized in that, The antibody is selected from at least one of polyclonal antibodies, full-length monoclonal antibodies, Fab antibodies, Fab' antibodies, F(ab')2 antibodies, Fv antibodies, and single-chain antibodies.

14. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the antibody as described in any one of claims 1 to 13.

15. A carrier, characterized in that, The carrier comprises the nucleic acid molecule of claim 14.

16. A cell, characterized in that, The cell comprises the nucleic acid molecule of claim 14 or the carrier of claim 15; The cells in question are non-plant cells.

17. A method for preparing the antibody according to any one of claims 1 to 13, characterized in that, The method includes culturing the cells of claim 16.

18. A coupling, characterized in that, include: The antibody and the conjugated portion thereof as described in any one of claims 1 to 13; The coupling portion is selected from at least one of purification tags, affinity substances, markers, and solid-phase supports; The affinity substance is selected from at least one of biotin or streptavidin.

19. The coupling according to claim 18, characterized in that, The purification label includes at least one of the following: His label, Flag label, GST label, MBP label, SUMO label, and C-Myc label.

20. The coupling according to claim 18, characterized in that, The solid support is selected from at least one of microspheres, plates, and membranes.

21. The coupling according to claim 18, characterized in that, The marker is selected from at least one of fluorescent dyes, enzymes, radioisotopes, chemiluminescent reagents, and nanoparticle markers.

22. A reagent or kit, characterized in that, include: The antibody according to any one of claims 1 to 13 or the conjugate according to any one of claims 18 to 21.

23. Use of the antibody according to any one of claims 1 to 13, the conjugate according to any one of claims 18 to 21, or the reagent or kit according to claim 22 in the preparation of a product for detecting cTnI.

Images